Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of adenocarcinoma of the
             prostate

          -  Patient must have a history/physical examination with digital rectal examination of
             the prostate within 90 days prior to screening

          -  Eastern Cooperative Oncology Group (ECOG) performance status must be level 0 or 1
             within 60 days prior to registration

          -  Patient must have a histological evaluation of the prostate biopsy with assignment of
             a Gleason score to the biopsy material; Gleason scores ≤ 7(3+4)

          -  Serum creatinine ≤ 1.5 times upper limit of institutional normal (normal: ≤ 1.17
             mL/min/1.73 m^2)

          -  Clinical stage a ≤ T1-T2a (American Joint Committee on Cancer [AJCC] 7th edition)

          -  Prostate specific antigen (PSA) ≤ 10 ng/mL within 90 days prior to registration; PSA
             should not be obtained within 10 days after prostate biopsy

          -  Subjects must have the ability to understand and the willingness to sign a written
             informed consent document

          -  Patient willing and able to complete the Expanded Prostate Cancer Index Composite
             (EPIC) questionnaire (baseline, 6, 12 and 24 months post end of radiation therapy)

          -  Patients must be able to undergo an MRI with contrast

          -  Bone scan completed within 90 days

        Exclusion Criteria:

          -  Evidence of distant metastases

          -  Regional lymph node involvement

          -  Previous radical surgery (prostatectomy), cryosurgery, or high intensity focused
             ultrasound (HIFU) for prostate cancer

          -  Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy

          -  Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH)
             agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix),
             anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., diethylstilbestrol
             [DES]), or surgical castration (orchiectomy)

          -  Use of finasteride within 30 days prior to registration; PSA should not be obtained
             prior to 30 days after stopping finasteride

          -  Use of dutasteride within 90 days prior to registration; PSA should not be obtained
             prior to 90 days after stopping dutasteride

          -  Previous or concurrent cytotoxic chemotherapy for prostate cancer

          -  Severe, active co-morbidity, defined as follows:

          -  Unstable angina and/or congestive heart failure requiring hospitalization within the
             last 6 months

          -  Transmural myocardial infarction within the last 6 months

          -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time of
             registration

          -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
             requiring hospitalization or precluding study therapy at the time of registration

          -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note,
             however, that laboratory tests for liver function and coagulation parameters are not
             required for entry into this protocol; (patients on Coumadin or other blood thinning
             agents are eligible for this study)

          -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and
             Control (CDC) definition; note, however, that human immunodeficiency virus (HIV)
             testing is not required for entry into this protocol; protocol-specific requirements
             may also exclude immuno-compromised patients

          -  Patients unable to undergo an MRI with contrast